Article
KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.
International journal of cancer - 15 Jun 2014
Kohonen-Corish Maija R J, Tseung Jason, Chan Charles, Currey Nicola, Dent Owen F, Clarke Stephen, Bokey Les, Chapuis Pierre H
Abstract excerpt
Colonic and rectal cancers differ in their clinicopathologic features and treatment strategies. Molecular markers such as gene methylation, microsatellite instability and KRAS mutations, are becoming increasingly important in guiding treatment decisions in colorectal cancer. However, their associ...
Topics
- Adult
- Aged
- Aged, 80 and over
- CpG Islands
- Cyclin-Dependent Kinase Inhibitor p16
- DNA Methylation
- DNA, Neoplasm
- Female
- Humans
- Male
- Microsatellite Instability
- Middle Aged
- Mutation
- Neoplasm Recurrence, Local
- Promoter Regions, Genetic